Zusammenfassung
Die Invasion von Tumorzellen tritt früh im Rahmen der lokalen Tumorprogression aggressiver Urothelkarzinome auf. Eine Mikrometastasierung in Lymph- oder Blutgefäße sowie das Vorhandensein von Lymphknotenmetastasen sind wichtige Prognosefaktoren für die krankheitsspezifische Mortalität. Der Metastasierungsprozess ist komplex und umfasst eine Kaskade multipler aufeinanderfolgender Schritte.
Für das Urothelkarzinom existieren wenige Daten aus präklinischen Studien über diese Mechanismen. Verschiedene Proteasen, Chemokine und Wachstumsfaktoren sind am Metastasierungsprozess beteiligt und pathophysiologische Veränderungen des Lymphgefäßsystems begünstigen die systemische Aussaat von Tumorzellen. Es besteht ein hoher Bedarf, neue Therapiemöglichkeiten zu entwickeln mit dem Ziel, in den Metastasierungsprozess einzugreifen.
Wir fassen Erkenntnisse über die Invasion und Metastasierung des Urothelkarzinoms zusammen und präsentieren ein innovatives experimentelles Modell, das funktionelle Aspekte berücksichtigt und dazu beitragen kann, die Mechanismen der Invasion besser zu verstehen sowie neue therapeutische Zielstrukturen zu identifizieren.
Abstract
Local invasion of cancer cells occurs early during the progression of urothelial carcinoma. Micrometastatic disease and the presence of nodal metastases are major causes of cancer-specific mortality following radical surgery. Only surrogate markers for aggressive and micrometastatic disease have been identified. The metastatic cascade is complex, including multiple steps from initial invasion to colonization and proliferation at distant sites.
The initial mechanisms of cancer cell dissemination in urothelial carcinoma are poorly understood. Various proteases, chemokines and growth factors are involved in this process and alterations of the lymphatic system may promote systemic spread. There is a high demand for therapeutic targeting of the metastatic process. Functional preclinical studies in representative models are therefore required to better elucidate the multiple steps of progression.
We review the current knowledge on factors associated with metastasis in urothelial carcinoma. Preclinical approaches to identify key player molecules for invasion and to develop new therapeutic strategies are discussed.
Literatur
Bolenz C, Auer M, Strobel P et al (2012) The lymphatic system in clinically localized urothelial carcinoma of the bladder: morphologic characteristics and predictive value. Urol Oncol. doi:10.1016/j.urolonc.2012.02.012 (Epub ahead of print)
Bolenz C, Fernandez MI, Trojan L et al (2009) Lymphangiogenesis occurs in upper tract urothelial carcinoma and correlates with lymphatic tumour dissemination and poor prognosis. BJU Int 103:1040–1046
Bolenz C, Gorzelanny C, Knauf D et al (2013) Assessing the invasive potential of bladder cancer: development and validation of a new preclinical assay. J Urol 189:1939–1944
Bolenz C, Herrmann E, Bastian PJ et al (2010) Lymphovascular invasion is an independent predictor of oncological outcomes in patients with lymph node-negative urothelial bladder cancer treated by radical cystectomy: a multicentre validation trial. BJU Int 106:493–499
Bolenz C, Lotan Y (2008) Molecular biomarkers for urothelial carcinoma of the bladder: challenges in clinical use. Nat Clin Pract Urol 5:676–685
Bolenz C, Shariat SF, Edwards T et al (2009) Expression of multiple biomarkers is associated with locally advanced urothelial carcinoma of the bladder in a prospective evaluation. J Urol 181:374
Christofori G (2006) New signals from the invasive front. Nature 441:444–450
Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161–174
Fernandez MI, Bolenz C, Trojan L et al (2008) Prognostic implications of lymphangiogenesis in muscle-invasive transitional cell carcinoma of the bladder. Eur Urol 53:571–578
Fidler IJ (2002) Critical determinants of metastasis. Semin Cancer Biol 12:89–96
Goerge T, Barg A, Schnaeker EM et al (2006) Tumor-derived matrix metalloproteinase-1 targets endothelial proteinase-activated receptor 1 promoting endothelial cell activation. Cancer Res 66:7766–7774
Herrmann E, Eltze E, Kopke T et al (2007) New markers for pharmacological targeting in bladder cancer with lymph node metastasis. Aktuelle Urol 38:392–397
Jager T, Becker M, Eisenhardt A et al (2010) The prognostic value of cadherin switch in bladder cancer. Oncol Rep 23:1125–1132
Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61:69–90
Karpanen T, Alitalo K (2008) Molecular biology and pathology of lymphangiogenesis. Ann Rev Pathol 3:367–397
Kesler CT, Liao S, Munn LL et al (2013) Lymphatic vessels in health and disease. Wiley Interdiscip Rev Syst Biol Med 5:111–124
Knauf D, Gorzelanny C, Schneider SW et al (2012) Invasive growth of urothelial carcinoma of the bladder: functional role of matrix metalloproteinases-2, -7 and -9. Urologe 51:126
Lotan Y, Gupta A, Shariat SF et al (2005) Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. J Clin Oncol 23:6533–6539
Ludwig T, Ossig R, Graessel S et al (2002) The electrical resistance breakdown assay determines the role of proteinases in tumor cell invasion. Am J Physiol Renal Physiol 283:319–327
Margulis V, Lotan Y, Montorsi F et al (2008) Predicting survival after radical cystectomy for bladder cancer. BJU Int 102:15–22
Martini T, Von Hardenberg J, Knauer A et al (2012) Expression der lymphspezifischen Marker VEGF-D, Flt-4, VEGF-C und CCR7 beim Urothelkarzinom der Harnblase. Assoziation mit histopathologischen Parametern und klinischem Verlauf. Urologe 51:80
Misumi T, Yamamoto Y, Miyachika Y et al (2012) DNA copy number aberrations associated with lymphovascular invasion in upper urinary tract urothelial carcinoma. Cancer Genet 205:313–318
Nisato RE, Tille JC, Pepper MS (2003) Lymphangiogenesis and tumor metastasis. Thromb Haemost 90:591–597
Retz MM, Sidhu SS, Blaveri E et al (2005) CXCR4 expression reflects tumor progression and regulates motility of bladder cancer cells. Int J Cancer 114:182–189
Shariat SF, Karakiewicz PI, Palapattu GS et al (2006) Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol 176:2414–2422 (discussion 2422)
Shariat SF, Youssef RF, Gupta A et al (2010) Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers. J Urol 183:1744–1750
Stein JP, Lieskovsky G, Cote R et al (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19:666–675
Szarvas T, Vom Dorp F, Ergun S et al (2011) Matrix metalloproteinases and their clinical relevance in urinary bladder cancer. Nat Rev Urol 8:241–254
Thiery JP, Acloque H, Huang RY et al (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139:871–890
Van Zijl F, Krupitza G, Mikulits W (2011) Initial steps of metastasis: cell invasion and endothelial transmigration. Mutat Res 728:23–34
Einhaltung ethischer Richtlinien
Interessenkonflikt. C. Bolenz, T. Martini und M.S. Michel geben an, dass kein Interessenkonflikt besteht. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bolenz, C., Martini, T. & Michel, M. Invasionsmechanismen und Metastasierung des Urothelkarzinoms. Urologe 52, 1242–1247 (2013). https://doi.org/10.1007/s00120-013-3309-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00120-013-3309-z